financetom
Business
financetom
/
Business
/
Vietnamese airlines sign $30-billion deals for 90 Boeing jets
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Vietnamese airlines sign $30-billion deals for 90 Boeing jets
Mar 11, 2026 4:39 AM

HANOI, Feb 19 (Reuters) - Three Vietnamese airlines signed deals with U.S. manufacturer Boeing ( BA ) on Thursday to buy a total of 90 aircraft, as Vietnam and the ​United States continue negotiations on a ‌new trade deal.

The deals were signed during a visit to the United ⁠States by the head of Vietnam's Communist Party, To ⁠Lam, to attend the inaugural meeting of ‌the Board of ‌Peace, an initiative launched by U.S. President Donald Trump to address ​global conflicts.

Vietnam Airlines signed a $8.1-billion ‌agreement with Boeing ( BA ) to buy 50 narrow-body 737-8 jets, Vietnam Airlines said in a statement.

The airline ​is scheduled to take ​delivery of ‌the aircraft between 2030 and 2032, it said in a statement, adding that this would increase its ⁠total fleet to approximately 151 aircraft by 2030.

The ⁠country's flag carrier is also in talks with Boeing ( BA ) for the additional purchase of 30 wide-body planes with a value of up to $12 billion, it said.

Vietnam's newly established ⁠Sun ‌PhuQuoc Airways also signed a $22.5 billion deal ‌with Boeing ( BA ) on Thursday to buy 40 787-9 Dreamliner ⁠jets, it said.

Meanwhile, Vietnamese budget airline Vietjet secured a $965 million financing deal with Griffin Global Asset Management for the purchase of 6 Boeing 737-8 aircraft.

Vietnam said early this month that it was willing to buy more American goods after the White ​House announced in October that the United States would keep tariffs on most Vietnamese goods at 20% while removing ​duties on certain products.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Founder Group Limited Filed For Us IPO Of Up To 2.5 Mln Ordinary Shares - SEC Filing
BRIEF-Founder Group Limited Filed For Us IPO Of Up To 2.5 Mln Ordinary Shares - SEC Filing
Aug 1, 2024
Aug 1 (Reuters) - FOUNDER GROUP LIMITED: * FOUNDER GROUP LIMITED FILED FOR US IPO OF UP TO 2.5 MILLION ORDINARY SHARES - SEC FILING * FOUNDER GROUP LTD SAYS EXPECTS U.S. IPO PRICE OF ORDINARY SHARES TO BE IN RANGE OF $4.00 TO $5.00 PER SHARE * FOUNDER GROUP LTD: INTEND TO RESERVE SYMBOL FGL FOR PURPOSES OF LISTING...
Littelfuse Insider Sold Shares Worth $1,037,079, According to a Recent SEC Filing
Littelfuse Insider Sold Shares Worth $1,037,079, According to a Recent SEC Filing
Aug 1, 2024
01:00 PM EDT, 08/01/2024 (MT Newswires) -- David W Heinzmann, Director, President & CEO, on July 31, 2024, sold 3,786 shares in Littelfuse ( LFUS ) for $1,037,079. Following the Form 4 filing with the SEC, Heinzmann has control over a total of 59,654 shares of the company, with 59,654 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/889331/000088933124000163/xslF345X03/form4.xml Price: 256.34, Change: -10.78,...
Honda Motor, Nissan to Collaborate on Research for New Software-Defined Vehicle Technologies
Honda Motor, Nissan to Collaborate on Research for New Software-Defined Vehicle Technologies
Aug 1, 2024
12:59 PM EDT, 08/01/2024 (MT Newswires) -- Honda Motor ( HMC ) and Nissan Motor said Thursday they agreed to conduct joint research into technology platforms for next-generation software-defined vehicles. The agreement is based on a memorandum of understanding, or MOU, the companies signed in March to start talks on a partnership for the age of intelligence and electrification, according...
Arbutus Biopharma to Reduce Workforce by 40% to Focus on Hepatitis B Treatment Imdusiran
Arbutus Biopharma to Reduce Workforce by 40% to Focus on Hepatitis B Treatment Imdusiran
Aug 1, 2024
01:02 PM EDT, 08/01/2024 (MT Newswires) -- Arbutus Biopharma ( ABUS ) said Thursday that it is cutting its workforce by 40% to focus its resources on imdusiran, which is intended to reduce all hepatitis B viral antigens. We intend to focus our existing resources on conducting a phase 2b clinical trial with imdusiran, assuming continued positive data, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved